Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 
 

Hatch-Waxman

services overview
Hatch-Waxman Image

Litigation

Post-Grant

Prosecution & Counseling

For more than a century, Fish has helped life sciences companies through waves of change within their industries by providing comprehensive advice and guidance to protect proactively their intellectual property and other assets.

Our practice includes Hatch-Waxman and other patent litigation for leading pharmaceutical companies, appellate victories that have had broad-ranging impact on the development of patent law, and several of the most significant patent cases of the past decade.

When representing innovator drug companies, we pursue multiple strategies to maximize returns on our clients’ investments during market exclusivity periods.

We do this by taking an interdisciplinary approach— ensuring that all scientific issues are understood fully throughout the product development and protection process. From the earliest stages of Hatch-Waxman litigation, we bring together the best team within the ranks of our firm to strategize the best course of action that will achieve our clients’ objectives.

This fully integrated approach—everything from pre-suit investigations to PTO actions, Orange Book tactics, Title I strategies of the Hatch-Waxman Act, ANDA filings (especially certification requirements pursuant to Paragraph IV), and FDA affairs—has proven invaluable to our clients in pharmaceutical litigation. Hatch-Waxman may be the door to the courthouse, but once in front of a judge or jury, you must still litigate the underlying science, and it is there that the Fish differential becomes evident.

We consistently deploy legal strategies and tactics that leverage our intellectual property, litigation, regulatory practices and technical expertise to achieve results for our pharmaceutical and life sciences clients. See below for our most recent client representation in the Hatch-Waxman industry.

Learn more about our experience in the life sciences industry.



Hatch-Waxman Minute: Part 1

"You've been handed a Paragraph IV letter, now what?"

Hatch-Waxman Minute: Part 2

"Retaining documents once the Paragraph IV letter is received"

Hatch-Waxman Series

Hatch-Waxman Minute
Parts 3-7

Related Pages

Litigation Blog
Litigation

Search Fish Hatch-Waxman Team Search

What's Trending in Hatch-Waxman

Filter by
Event
六月 16th, 2020 | 1:30 下午 EST
Webinar | Hatch-Waxman: Positioning Your Company For Success Against Generic Challenges
Webinar
Event
三月 27th, 2019 | 1:00 下午 EST
Webinar: Hatch-Waxman and IPR Strategy
Webinar
Event
四月 7th, 2019 | 12:00 上午 EST
Patent Resources Group (PRG) Spring 2019 Advanced Courses Program
Speaking Engagement
Event
一月 17th, 2019 | 1:00 下午 EST
Webinar | 2018 Biosimilars – A Year in Review
Webinar
Event
四月 26th, 2018 | 12:00 上午 EST
Life Sciences Patent Network North America
Speaking Engagement
Event
五月 31st, 2018 | 1:00 下午 EST
Webinar: Hatch-Waxman 301
Webinar
Event
一月 25th, 2018 | 1:00 下午 EST
Webinar: Hatch-Waxman 201
Webinar
Event
十二月 6th, 2017 | 1:00 下午 EST
Webinar: Hatch-Waxman 101
Webinar
Event
九月 28th, 2017 | 11:30 上午 EST
BPLA Biotechnology Committee: PTAB/Hatch-Waxman Parallel Proceedings
Speaking Engagement
Q&A
April 3, 2017
Q&A with Susan Morrison: Patent Lawyer and Scientist Inspiring Women in STEM
Hatch-Waxman
Litigation
Patent
IP
Diversity
STEM
Q&A
March 22, 2017
Q&A with Chad Shear: A Big Year Is Expected in Life Sciences Patent Litigation
Hatch-Waxman
Life Sciences
Litigation
Patent
Non-Practicing Entities
IP
Trends
Event
一月 18th, 2017 | 12:00 上午 EST
Boston Seminar Series | Life Sciences Patents 2016 Year in Review
Speaking Engagement
load more topics